Scientists find the molecular switch H. pylori flips to inflame the stomach

If you've ever wondered why a bacterium as common as Helicobacter pylori (H. pylori) can quietly inflame one person's stomach for decades while barely bothering another, researchers just found a piece of the answer. A new study out of Army Medical University in China, published in the Journal of Army Medical University, identifies a stomach-cell receptor called GPRC5C as a previously unreported driver of H. pylori-triggered gastritis (inflammation of the stomach lining), and shows that switching the gene off protects mice from the inflammation the bacterium normally causes. The finding held up across infected mice, infected human stomach tissue, and infected cells in a dish, which is the kind of triangulation that makes a mechanism worth taking seriously.

Key takeaways:

• H. pylori infection turns on a stomach-cell receptor called GPRC5C by activating NF-κB, a master inflammation switch inside cells.
• Mice engineered to lack GPRC5C developed significantly less stomach inflammation after H. pylori infection than normal mice, at the same infection dose and duration.
• The same pattern showed up in infected mouse stomachs, infected human stomach tissue, and infected cells in culture, not just one model system.
• The knockout comparison that shows GPRC5C actually causes inflammation (rather than just tracking along with it) used only 5 mice per group, so it's a strong first signal, not a settled fact.

H. Pylori Switches On GPRC5C by Activating NF-κB

H. pylori infection drives up GPRC5C (a receptor protein on the surface of stomach-lining cells, part of a family called G protein-coupled receptors) by activating NF-κB, a signaling protein that acts as a master switch for inflammation inside cells. GPRC5C is not a new discovery. It's already known for jobs unrelated to infection, like keeping blood stem cells dormant and helping control blood vessel constriction. But its role during a bacterial infection had never been reported until this study. The researchers tested it in human gastric epithelial cells (GES-1, a standard lab line) and in primary gastric epithelial cells pulled directly from mouse stomachs, and infection reliably pushed GPRC5C's mRNA output up 4.1-fold in the human cell line and 3.1-fold in the mouse primary cells (P<0.01). The more bacteria they added and the longer the infection ran, the higher GPRC5C climbed, a dose- and time-dependent pattern that is a classic signature of a real biological response rather than noise.

Why Chronic Gastritis Patients Should Care

H. pylori already infects roughly about half the world's population, and long-term infection is the leading cause of chronic gastritis, a major risk factor for peptic ulcers and one of the strongest known risk factors for stomach cancer. Anyone managing chronic gastritis, recurring stomach pain, or a positive H. pylori test that antibiotics haven't fully resolved is dealing with the downstream effects of exactly the kind of inflammatory signaling this study maps out. Antibiotic resistance in H. pylori has been climbing for years, which is part of why researchers are hunting for treatment targets that don't rely on killing the bacteria outright. A receptor that amplifies the damage after infection, rather than the bacteria itself, is a different kind of target: block the host's overreaction instead of (or alongside) clearing the germ.

How the Study Was Built: Mice, Human Tissue, and Two Cell Types

This wasn't a single quick experiment. The researchers infected 190 SPF-grade female mice (95 infected with H. pylori, 95 given a placebo gavage), then euthanized 5 mice per group every week for 19 weeks to track how GPRC5C rose over the full course of a chronic infection, finding it peaked at week 14 post-infection (P<0.0001). They confirmed the same elevation in non-tumor stomach tissue taken from gastric cancer patients at their affiliated hospital, comparing tissue from H. pylori-positive and H. pylori-negative patients. In the lab, they infected two separate cell types (the human GES-1 line and primary mouse gastric epithelial cells) at multiple bacterial doses and time points. To pin down the mechanism, they pretreated cells with eight different signaling-pathway blockers before infecting them; only the NF-κB inhibitor, BAY 11-7082, blunted the GPRC5C response, cutting it by 64.0% (P<0.01), and a reporter-gene assay showed H. pylori infection boosted GPRC5C's own gene-promoter activity to 4.1 times the uninfected level (P<0.001), an effect the same NF-κB inhibitor suppressed by 66.1% (P=0.0002). Finally, to test whether GPRC5C actually causes damage rather than just rising alongside it, they bred mice with the GPRC5C gene deleted entirely and infected them alongside normal mice.

What This Means If You're Watching Your Own Gut Health

This is a mechanism discovery, not a treatment. There is no GPRC5C-blocking drug, supplement, or test available to patients right now, and nothing here changes standard H. pylori care, which still means antibiotic eradication therapy under a doctor's guidance. What it does offer is a more precise answer to "why does this infection cause so much inflammation in some people," and a specific molecular handle (GPRC5C, sitting downstream of NF-κB) that drug developers can now try to target. If you have chronic gastritis or a confirmed H. pylori infection, this doesn't change what's worth asking your doctor today, but it is the kind of finding that shapes what "next-generation" H. pylori treatments look like over the coming years, since it points toward calming the inflammatory response itself rather than only killing the bacteria.

What's Still Unproven, and What's Missing

The functional proof that GPRC5C causes worse inflammation, not just correlates with it, comes from comparing gene-deleted mice to normal mice at just 5 animals per group, a small cohort for a causal claim, even though the difference the authors measured was statistically significant (P<0.001) and matched what the rest of the data predicted. The researchers also don't yet know what molecule directly triggers GPRC5C during infection (its natural activating signal, or "ligand," in this context is still unidentified), and they haven't mapped which downstream inflammatory signals GPRC5C sends out or which immune cells get recruited as a result. It's also worth noting the study didn't identify which specific H. pylori virulence factor flips on NF-κB in this pathway; other H. pylori proteins are already known to activate NF-κB through a toxin called CagA or through another inflammatory protein called ANGPTL4, and this study doesn't say whether GPRC5C sits downstream of those same triggers or a separate one.

What Comes Next

The authors frame this as a foundation for two follow-up directions: identifying GPRC5C's natural ligand in the stomach environment, and mapping the downstream chemokine signals and immune-cell recruitment GPRC5C controls, using techniques like mass spectrometry and single-cell sequencing. Only once that downstream biology is mapped would GPRC5C become a plausible drug target for actually blocking H. pylori-driven inflammation. No timeline for human trials or drug development was given, and none should be expected soon; this is still early-stage mechanistic biology.

Common Questions

Does this mean GPRC5C causes stomach cancer? Not directly. This study looked at gastritis (inflammation), not cancer, though chronic H. pylori-driven gastritis is a well-established risk factor for gastric cancer. The human tissue samples came from gastric cancer patients, but only as a source of normal, non-tumor stomach tissue to check GPRC5C levels, not as evidence GPRC5C drives tumors.

Should I ask my doctor about a GPRC5C test or treatment? No, there isn't one. This is a lab discovery, not a clinical tool. Standard H. pylori testing and antibiotic-based eradication therapy remain the current standard of care.

Is this relevant if I don't have H. pylori? Only indirectly. The pathway described here is specific to how this particular bacterium provokes inflammation, though the same GPRC5C-NF-κB link, or something similar, could plausibly turn out to matter in other inflammatory gut conditions; that hasn't been tested here.

References

S Luo, P Wang, A Wang, Y Zhuang (2026). Helicobacter Pylori Infection Promotes Gastric Inflammation by Upregulating GPRC5C in Gastric Epithelial Cells via Activation of the NF-ΚB Pathway. Journal of Army Medical University. https://doi.org/10.16016/j.2097-0927.202604087